Adaptive and self-adaptive plasma cancer therapeutic platform

Patent metadata

Field	Value
Publication number	US-11517366-B2
Application number	US-201816492888-A
Country	US
Kind code	B2
Filing date	Mar 13, 2018
Priority date	Mar 13, 2017
Publication date	Dec 6, 2022
Grant date	Dec 6, 2022

Abstract

A method and system of adaptive cold atmospheric based treatment for diseased tissues, such as an area with cancerous cells, is disclosed. A plasma device generates a cold atmospheric plasma jet directed at the area having cancerous cells. A sensor is operable to sense the viability of the cancerous cells in the area. A controller is coupled to the plasma device and sensor. The controller is operative to control an initial plasma jet generated by the plasma device. The controller receives a sensor signal from the sensor to determine cell viability of the selected cells from the initial plasma jet. The controller adjusts the plasma jet based on the viability of the cancerous cells.

First claim

What is claimed is:

1. A system for treatment of an area having cells, comprising:
a plasma device to generate a cold atmospheric plasma jet directed at the area having cells;
a sensor operable to generate a sensor signal based on sensing the viability of selected cells in the area; and
a controller coupled to the plasma device and the sensor, the controller operative to:
control an initial plasma jet generated by the plasma device;
receive the sensor signal from the sensor;
determine cell viability of the selected cells based on the sensor signal;
executing a real-time feedback algorithm to determine whether and how to adjust the initial plasma jet to produce a modified plasma jet to change the determined cell viability to a targeted cell viability level; and
adjust the initial plasma jet to produce the modified plasma jet in real-time.

2. The system of claim 1 , wherein the selected cells are cancerous cells.

3. The system of claim 2 , wherein the cancerous cells are one of brain cancer cells, breast cancer cells, pancreatic cancer cells, skin cancer cells, bladder cancer cells, colon cancer cells, or lung cancer cells.

4. The system of claim 1 , wherein the plasma jet generates an oxygen or nitrogen reactive species.

5. The system of claim 1 , further comprising a magnetic field generator to generate a magnetic field over the area.

6. The system of claim 1 , further comprising an actuator coupled to the controller, wherein the controller is operative to control the actuator to change the position of the plasma device relative to the area.

7. The system of claim 1 , further comprising a power regulator coupled to the controller, wherein the controller is operative to change a discharge voltage or a discharge current of the plasma device via the power regulator.

8. The system of claim 1 , wherein the controller is operative to change gas flow or gas composition generating the plasma jet.

9. The system of claim 1 , further comprising a nanoparticle injector to inject nano particles into the area.

10. The system of claim 9 , wherein medication is injected with the nano-particles.

11. The system of claim 1 , wherein a marker material is injected in the area.

12. The system of claim 11 , wherein the sensor is a luminescence sensor coupled to the controller, the luminescence sensor in proximity to the area, wherein the marker material generates a luminesce luminescence level when attached on live cells in the area.

13. The system of claim 1 , wherein the sensor is H 2 O 2 molecule chemical probe, and wherein the sensor signal is associated with H 2 O 2 molecules generated by the cancerous cells in the area.

14. The system of claim 13 , wherein the sensor is a UV-visible spectrometer.

15. The system of claim 1 , wherein the control of the initial plasma jet includes setting different parameters, and wherein the controller is further operative to select at least one of the different parameters to adjust to produce the modified plasma based on the determined cell viability.

16. The system of claim 15 , wherein the different parameters are at least one of the group consisting of discharge voltage, reactive species composition, and gas flow.

17. A method of treating an area having cells, the method comprising:
ionizing a gas via a plasma device to create an initial cold atmospheric plasma jet;
directing the initial plasma jet toward the area having cells;
sensing cell viability of selected cells in the area with a sensor operable to generate a sensor signal based on the viability of selected cells in the area;
receiving the sensor signal from the sensor;
determining cell viability of the selected cells based on the sensor signal via a controller;
executing a real-time feedback algorithm via the controller to determine whether and how to adjust the initial plasma jet to produce a modified plasma jet to change the determined cell viability to a targeted cell viability level; and
adjusting the initial plasma jet to produce the modified plasma jet in real-time.

18. The method of claim 17 , wherein the selected cells are cancerous cells.

19. The method of claim 18 , wherein the cancerous cells are one of brain cancer cells, breast cancer cells, pancreatic cancer cells, skin cancer cells, bladder cancer cells, colon cancer cells, or lung cancer cells.

20. The method of claim 17 , wherein the plasma jet generates an oxygen or nitrogen reactive species.

21. The method of claim 17 , further comprising generating a magnetic field over the area via a magnetic field generator.

22. A system for treatment of an area having cancerous cells, comprising:
a plasma device to generate a cold atmospheric plasma jet directed at the area having cancerous cells;
a marker material in the area, the marker material producing a luminescence level relative to the viability of the cancerous cells;
a luminescence sensor to generate a sensor signal on sensing the luminescence level of the cancerous cells; and
a controller coupled to the plasma device and luminescence sensor, the controller operative to: control an initial plasma jet generated by the plasma device; measure the luminescence of the markers in the area from the sensor signal; to determine cell viability from the initial plasma jet; execute a real-time feedback algorithm to determine whether and how to adjust the plasma jet to produce a modified plasma jet to change the determined cell viability to a targeted cell viability level; and adjust the initial plasma jet to produce the modified plasma jet in real-time.

Assignees

• Univ George Washington

Inventors

• Keidar Michael

Classifications

• A61B18/042 Primary

  using additional gas becoming plasma · CPC title

• A61B2018/00642

  with feedback, i.e. closed loop control · CPC title

• B82Y5/00

  Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title

• A61B2018/00583

  Coblation, i.e. ablation using a cold plasma · CPC title

• A61B2018/00446

  Brain · CPC title